Investor Overview

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has a collaboration agreement with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

Upcoming Events

There are currently no events to display.